Trillium Therapeutics (TRIL) Cut to “Sell” at ValuEngine

ValuEngine lowered shares of Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) from a hold rating to a sell rating in a research report sent to investors on Friday morning.

Other analysts also recently issued reports about the stock. Zacks Investment Research raised shares of Trillium Therapeutics from a hold rating to a buy rating and set a $12.00 price objective for the company in a report on Thursday, November 23rd. HC Wainwright reaffirmed a buy rating and set a $10.00 price objective on shares of Trillium Therapeutics in a report on Thursday. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Trillium Therapeutics currently has a consensus rating of Buy and an average price target of $13.33.

Shares of Trillium Therapeutics (TRIL) opened at $7.55 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.33 and a quick ratio of 6.33. Trillium Therapeutics has a 1 year low of $4.15 and a 1 year high of $13.30.

Large investors have recently added to or reduced their stakes in the stock. Virtu KCG Holdings LLC acquired a new position in Trillium Therapeutics during the 2nd quarter valued at $128,000. K2 Principal Fund L.P. acquired a new position in Trillium Therapeutics during the 2nd quarter valued at $264,000. Victory Capital Management Inc. raised its stake in Trillium Therapeutics by 88.9% during the 2nd quarter. Victory Capital Management Inc. now owns 146,571 shares of the biotechnology company’s stock valued at $645,000 after purchasing an additional 68,970 shares during the last quarter. Sectoral Asset Management Inc raised its stake in shares of Trillium Therapeutics by 42.9% in the 2nd quarter. Sectoral Asset Management Inc now owns 183,272 shares of the biotechnology company’s stock valued at $806,000 after buying an additional 55,000 shares in the last quarter. Finally, Tekla Capital Management LLC acquired a new position in shares of Trillium Therapeutics in the 2nd quarter valued at $1,980,000. Hedge funds and other institutional investors own 47.45% of the company’s stock.

WARNING: This piece was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://sportsperspectives.com/2017/12/18/trillium-therapeutics-tril-cut-to-sell-at-valuengine.html.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply